Plus   Neg

FDA Approves Pfizer's Zirabev To Treat Five Types Of Cancer

Pfizer Inc. (PFE) said that the U.S. Food and Drug Administration has approved Zirabev, a biosimilar to Avastin, for the treatment of five types of cancer.

They are metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.

Zirabev is a mAb biosimilar of the reference product, Avastin, which works by inhibiting the formation of new blood cells by specifically recognizing and binding to vascular endothelial growth factor protein.

For comments and feedback contact: editorial@rttnews.com

Follow RTT